-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
April 2021
-
The Importance of Shared Decision Making: A Patient’s Perspective on Skin Toxicity with Afatinib/Cetuximab
Although the importance of multidisciplinary care teams is known, unfortunately, cross-specialty knowledge is not always solicited or recommended
-
IASLC Establishes Global Molecular Database for Thoracic Malignancies: A Call for Data
The IASLC has established authority as the only global multidisciplinary organization dedicated to overcoming the four major thoracic malignancies- esophageal cancer, lung cancer, mesothelioma, and thymic malignancies. As we enter the molecular age with the promise that personalized cancer treatment will improve treatment and outcomes for our patients, major barriers are arrayed before us. How…
-
A National Network Provides a Window into Lung Cancer Screening Trends, Successes across the United States
Now that the positive impact of lung cancer screening on mortality and morbidity is irrefutable, there is an obvious need to find new ways to overcome consistent challenges with implementation of screening programs. It is difficult for just a single center to define and maintain logistical standards, track and improve return rates, and implement emerging…
-
Christian Rolfo to Move to Mount Sinai
Christian Rolfo, MD, PhD, will take the reins as associate director for clinical research in the Center for Thoracic Oncology/Tisch Cancer Institute, Mount Sinai, New York. Previously, Dr. Rolfo served as director of thoracic medical oncology and early clinical trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center and as a…
-
Olaparib Maintenance Did Not Improve PFS, OS in Platinum-Sensitive NSCLC
The PARP inhibitor olaparib did not improve PFS or OS compared with placebo when used as a maintenance therapy for patients with platinum-sensitive NSCLC, according to results of the phase II PIPSeN trial.1 Sophie Postel-Vinay, MD, PhD, of the Gustave Roussy Cancer Campus in France, presented results of the trial at the European Lung Cancer…
-
CheckMate 9LA Combination Effective in Advanced NSCLC Despite PD-L1 Expression, TMB Status
A higher tumor mutational burden (TMB) was associated with improved PFS and overall response rate for patients with advanced NSCLC treated with nivolumab plus ipilimumab plus chemotherapy compared with chemotherapy alone, according to results from CheckMate 9LA presented at the European Lung Cancer Virtual Congress 2021.1 No differences in outcomes among treatment arms were…
-
PACIFIC-R: Findings Reflect Clinical Reality of Consolidation Therapy in Stage III NSCLC
The real-world assessment of durvalumab in patients with unresectable stage III NSCLC in the PACIFIC-R trial has highlighted important differences between this population and that of the original randomized PACIFIC trial. Fiona McDonald, MD, MA, MBBS, MRCP, FRCR, of The Royal Marsden NHS Foundation Trust, London, United Kingdom, presented the baseline characteristics and initial…
-
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Con Side
The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeting, revealing a lack of benefit for…
-
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con – The Pro Side
The controversy about the role of post-operative radiation therapy (PORT) in patients with a completely resected stage III-N2 NSCLC may soon be settled with the forthcoming publication of the results of the randomized LungART trial. Study findings were presented at the 2020 European Society for Medical Oncology Annual Meeting, revealing a lack of benefit for…
-
Symposium Chairs Reflect on Current Status, Next Steps for Lung Cancer Screening on a Global Scale
It has been documented and accepted that lung cancer screening saves lives by detecting disease in high-risk individuals at earlier stages, making the disease more treatable and leading to improved survival and quality of life for these patients. Earlier treatment of disease also leads to exploration of new therapeutic models, which allows researchers and clinicians…